

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 February 2025 (06.02.2025)



(10) International Publication Number
WO 2025/027049 A1

(51) International Patent Classification:

A61P 25/00 (2006.01) C07D 413/12 (2006.01)
A61P 29/00 (2006.01) A61K 31/5375 (2006.01)
C07D 265/30 (2006.01)

(21) International Application Number:

PCT/EP2024/071621

(22) International Filing Date:

31 July 2024 (31.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23189263.9 02 August 2023 (02.08.2023) EP
24185413.2 28 June 2024 (28.06.2024) EP

(71) Applicant: **BOEHRINGER INGELHEIM INTERNATIONAL GMBH** [DE/DE]; Binger Strasse 173, 55216 INGELHEIM AM RHEIN (DE).

(72) Inventors: **HEHN, Joerg P.**; Boehringer Ingelheim International GmbH, Global Patents, Binger Strasse 173, 55216 INGELHEIM AM RHEIN (DE). **GIOVANNINI, Riccardo**; Boehringer Ingelheim International GmbH, Global Patents, Binger Strasse 173, 55216 INGELHEIM AM RHEIN (DE). **PROULX, Eliane**; Boehringer Ingelheim International GmbH, Global Patents, Binger Strasse 173, 55216 INGELHEIM AM RHEIN (DE). **SOMMER, Heiko**; Boehringer Ingelheim International GmbH, Global Patents, Binger Strasse 173, 55216 INGELHEIM AM RHEIN (DE). **SPECKER, Christian**; Boehringer Ingelheim International GmbH, Global Patents, Binger Strasse 173, 55216 INGELHEIM AM RHEIN (DE).

(74) Agent: **LUTZE, Oliver** et al.; Boehringer Ingelheim International GmbH, Global Patents, Binger Strasse 173, 55216 INGELHEIM AM RHEIN (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: (2S,5R)-5-(HYDROXYMETHYL)MORPHOLINE-2-CARBOXAMIDES AS AGONISTS OF SSTR4



(I)

(57) Abstract: The present disclosure provides *cis*-5-(hydroxymethyl)morpholine-2-carboxamides that are agonists of somatostatin receptor 4 (SSTR4), and are therefore useful for the treatment of diseases or medical conditions associated with SSTR4. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.



WO 2025/027049 A1